US0311621009 - Common Stock - After market: 244.7 +0.7 (+0.29%)
NASDAQ:AMGN (2/7/2023, 7:23:44 PM)+0.15 (+0.06%)
|GICS Sector||Health Care|
|Earnings (Last)||01-31 2023-01-31/amc||Earnings (Next)||04-25 2023-04-25/amc|
|Ins Owners||0.19%||Inst Owners||76.96%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 24,200 full-time employees. The firm discovers, develops, manufactures and delivers various human therapeutics. The company operates in human therapeutics segment. Its marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The firm focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.
One Amgen Center Drive
Thousand Oaks CALIFORNIA 91320
CEO: Robert A. Bradway
Teva Pharmaceutical (TEVA) is the latest drugmaker to leave the influential industry trade group PhRMA following a similar move AbbVie (ABBV) late last year. Read the full story here.
Bristol Myers Squibb has solid replacements for its blockbusters that are facing a patent cliff.
The major indexes continued to run despite mixed-to-weak earnings.
If you’re looking for the best deals among the most iconic enterprises, these are the most undervalued Dow stocks to buy.
Here you can normally see the latest stock twits on AMGN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.